Background: Interleukin (IL)-17A is a highly inflammatory cytokine with a robust effect on stromal cells in many tissues. Although IL-17A is known to be associated with inflammatory lung disorders by triggering an accumulation of neutrophils, the effect of IL-17A on the upper airway is still uncertain. The expression of IL-17A and its role were investigated in the nasal polyps of chronic rhinosinusitis associated with asthma. Methods: IL-17A was detected by immunohistochemistry and quantitative real-time RT-PCR. The cellular source of IL-17A was examined by double staining with EG2, CD4 and neutrophil elastase. The tissue remodeling of the nasal polyps was evaluated by assessing the epithelial damage and basement membrane thickness. Results: Both the immunoreactivity and mRNA of IL-17A were significantly detected in the nasal polyps in comparison with control normal sinus mucosa. The localization of IL-17A expression predominantly coincided with eosinophils and CD4-positive lymphocytes. Furthermore, the number of IL-17A-positive cells correlated with tissue eosinophils, but not with neutrophils. The degree of epithelial damage and basement membrane thickness was dependent on the number of infiltrated IL-17A-positive cells. Conclusion: The present study suggests, for the first time, that IL-17A plays an important role in the eosinophil accumulation in the nasal polyps and the remodeling of the nasal polyps of chronic rhinosinusitis associated with asthma.

Journal Section:
Editor's choice
Keywords:
Nasal polyps, Chronic rhinosinusitis, Asthma, Interleukin-17A
1.
Benninger MS, Ferguson BJ, Hadley JA, Hamilos DL, Jacobs M, Kennedy DW, Lanza DC, Marple BF, Osguthorpe JD, Stankiewicz JA, Anon J, Denneny J, Emanuel I, Levine H: Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 2003;129:S1–S32.
2.
Kaliner MA, Osguthorpe JD, Fireman P, Anon J, Georgitis J, Davis ML, Naclerio R, Kennedy D: Sinusitis: bench to bedside. Current findings, future directions. J Allergy Clin Immunol 1997;99:S829–S848.
3.
Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Bachert C, Baraniuk J, Baroody FM, Benninger MS, Brook I, Chowdhury BA, Druce HM, Durham S, Ferguson B, Gwaltney JM, Kaliner M, Kennedy DW, Lund V, Naclerio R, Pawankar R, Piccirillo JF, Rohane P, Simon R, Slavin RG, Togias A, Wald ER, Zinreich SJ: Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 2004;114:S155–S212.
4.
Fokkens W, Lund V, Mullol J: European position paper on rhinosinusitis and nasal polyps. Rhinology 2007;45(suppl 20):1–139.
5.
Polzehl D, Moeller P, Riechelmann H, Perner S: Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy 2006;61:1275–1279.
6.
van Zele T, Claeys S, Genaert P, van Maele G, Holtappels G, van Cauwenberge P, Bachert C: Differentiation of chronic sinus disease by measurement of inflammatory mediators. Allergy 2006;61:1280–1289.
7.
Eichel BS: A proposal for a staging system for hyperplastic rhinosinusitis based on the presence or absence of intranasal polyposis. Ear Nose Throat J 1999;78:262–265.
8.
Georgitis JW, Matthews BL, Stone B: Chronic sinusitis: characterization of cellular influx and inflammatory mediators in sinus lavage fluid. Int Arch Allergy Immunol 1995;196:416–421.
9.
Suzuki H, Wataya H, Takahashi Y, Ikeda K, Shimomura A, Nakabayashi S, Takasaka T: Mechanism of neutrophil recruitment induced by interleukin-8 in chronic sinusitis. J Allergy Clin Immunol 1996;98:659–670.
10.
Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T: Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med 1997;182:115–124.
11.
Suzuki H, Ikeda K: Mode of action of long-term low-dose macrolide therapy for chronic sinusitis in the light of neutrophil recruitment. Curr Drug Targ Inflamm Allergy 2000;1:117–126.
12.
Hamilos D, Leung DYM, Wood R, Meyers A, Stephens JK, Barkans J, Meng Q, Cunningham L, Bean DK, Kay AB, et al: Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993;92:39–48.
13.
Dinis PB, Gomes A: Sinusitis and asthma: how do they interrelate in sinus surgery? Am J Rhinol 1997;11:421–428.
14.
Dejima K, Hama T, Miyazaki M, Yasuda S, Fukushima K, Oshima A, Yasuda M, Hisa Y: A clinical study of endoscopic sinus surgery for sinusitis in patients with bronchial asthma. Int Arch Allergy Immunol 2005;138:97–104.
15.
Hamilos D: Chronic sinusitis. J Allergy Clin Immunol 2000;106:213–227.
16.
Steinke JW: The relationship between rhinosinusitis and asthma sinusitis. Curr Allergy Asthma Rep 2006;6:495–501.
17.
Slavin RG: Asthma and sinusitis. J Allergy Clin Immunol 1992;90:534–537.
18.
Bachert C, Gevaaert P, Holtappels G, Cuvelier C, Van Cauwenberge P: Nasal polyposis: from cytokines expressions to growth. Am J Rhinol 2000;14:279–290.
19.
Elhini A, Abdelwahab S, Ikeda K: Th1 and Th2 cell population in chronic ethmoidal rhinosinusitis: a chemokine receptor assay. Laryngoscope 2005;115:1272–1277.
20.
Naylor B: The shedding of the mucosa of the bronchial tree in asthma. Thorax 1962;17:69–72.
21.
Roche WR, Beasley R, Williams JH, Holgate ST: Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989;i:520–524.
22.
Ponikau JU, Sherris DA, Kephart GM, Kern EB, Gaffey TA, Tarara JE, Kita H: Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma? J Allergy Clin Immunol 2003;112:877–882.
23.
Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001–1008.
24.
Amin K, Lúdvíksdóttir D, Janson C, Nettelbladt O, Björnsson E, Roomans GM, Boman G, Sevéus L, Venge P: Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 2000;162:2295–2301.
25.
Gibson PG, Simpson JL, Saltos N: Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001;119:1329–1336.
26.
Douwes J, Gibson P, Pekkanen J, Pearce N: Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002;57:643–648.
27.
Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, Olivenstein R, Elias J, Chakir J: IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001;108:430–438.
28.
Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, Lam CW: Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001;125:177–183.
29.
Barczyk A, Pierzchala W, Sozañska E: Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 2003;97:726–733.
30.
Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, Ceuppens JL: IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 2006;7:135.
31.
Vanaudenaerde BM, Wuyts WA, Dupont LJ, Van Raemdonck DE, Demedts MM, Verleden GM: Interleukin-17 stimulates release of interleukin-8 by human airway smooth muscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003;22:1280–1283.
32.
Henness S, Johnson CK, Ge Q, Armour CL, Hughes JM, Ammit AJ: IL-17A augments TNF-alpha-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. J Allergy Clin Immunol 2004;114:958–964.
33.
Van Bruaene N, Pérez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, Schmidt-Weber C, Akdis C, Van Cauwenberge P, Bachert C, Gevaert P: T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008;121:1435–1441, 1441.e1–e3.
34.
Wang X, Dong Z, Zhu DD, Guan B: Expression profile of immune-associated genes in nasal polyps. Ann Otol Rhinol Laryngol 2006;115:450–456.
35.
Molet SM, Hamid QA, Hamilos DL: IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone propionate. Laryngoscope 2003;113:1803–1812.
36.
Fokkens W, Lund V, Bachert C, Clement P, Helllings P, Holmstrom M, Jones N, Kalogjera L, Kennedy D, Kowalski M, Malmberg H, Mullol J, Passali D, Stammberger H, Stierna P: EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy 2005;260:583–601.
37.
Ikeda K, Kondo Y, Sunose H, Hirano K, Oshima T, Shimomura A, Suzuki H, Takasaka T: Subjective and objective evaluation in endoscopic sinus surgery. Am J Rhinol 1996;10:217–220.
38.
Lund VJ, Mackay IS: Staging in rhinosinusitis. Rhinology 1993;31:183–184.
39.
Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Panizzolo C, Zanin ME, Zuin R, Maestrelli P, Fabbri LM, Saetta M: Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med 2006;174:975–981.
40.
Hamilos DL, Leung DY, Wood R, Cunningham L, Bean DK, Yasruel Z, Schotman E, Hamid Q: Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 1995;96:537–544.
41.
Van Bruaene N, Pérez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, Schmidt-Weber C, Akdis C, Van Cauwenberge P, Bachert C, Gevaert P: T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008;121:1435–1441, 1441.e1–e3.
42.
Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ: Human IL-17: a novel cytokine derived from T cells. J Immunol 1995;155:5483–5486.
43.
Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A: IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003;170:2106–2112.
44.
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123–1132.
45.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133–1141.
46.
Tesmer LA, Lundy SK, Sarkar S, Fox DA: Th17 cells in human disease. Immunol Rev 2008;223:87–113.
47.
Oboki K, Ohno T, Saito H, Nakae S: Th17 and allergy. Allergol Int 2008;57:121–134.
48.
Lindén A: Role of interleukin-17 and the neutrophil in asthma. Int Arch Allergy Immunol 2001;126:179–184.
49.
Dragon S, Rahman MS, Yang J, Unruh H, Halayko AJ, Gounni AS: IL-17 enhances IL-1beta-mediated CXCL-8 release from human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2007;292:L1023–L1029.
50.
Yao T, Kojima Y, Koyanagi A, Yokoi H, Saito T, Kawano K, Furukawa M, Kusunoki T, Ikeda K: Eotaxin-1, -2, and -3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients. Laryngoscope, in press.
51.
Rahman MS, Yamasaki A, Yang J, Shan L, Halayko AJ, Gounni AS: IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways. J Immunol 2006;177:4064–4071.
52.
Hellings PW, Kasran A, Liu Z, Vandekerckhove P, Wuyts A, Overbergh L, Mathieu C, Ceuppens JL: Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003;28:42–50.
53.
Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez F, Ryffel B, Schnyder B: Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006;203:2715–2725.
54.
Wakashin H, Hirose K, Maezawa Y, Kagami S, Suto A, Watanabe N, Saito Y, Hatano M, Tokuhisa T, Iwakura Y, Puccetti P, Iwamoto I, Nakajima H: IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med 2008;178:1023–1032.
55.
Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485–517.
56.
Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M, Boulet LP, Hamid Q: Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 2003;111:1293–1298.
57.
Saitoh T, Kusunoki T, Yao T, Kawano K, Kojima Y, Miyahara K, Onoda J, Yokoi H, Ikeda K: Relevance of epithelial damage and basement membrane thickness to eosinophilic infiltration in nasal polyps of chronic rhinosinusitis; submitted.
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.